- Home
- AUST vs LEXX Comparison
AUST vs LEXX Comparison
Compare AUST & LEXX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AUST
- LEXX
- Stock Information
- Founded
- AUST 2020
- LEXX 2004
- Country
- AUST Canada
- LEXX Canada
- Employees
- AUST N/A
- LEXX N/A
- Industry
- AUST
- LEXX Biotechnology: Pharmaceutical Preparations
- Sector
- AUST
- LEXX Health Care
- Exchange
- AUST Nasdaq
- LEXX Nasdaq
- Market Cap
- AUST 19.0M
- LEXX 19.6M
- IPO Year
- AUST 2022
- LEXX N/A
- Fundamental
- Price
- AUST $1.28
- LEXX $0.85
- Analyst Decision
- AUST
- LEXX Strong Buy
- Analyst Count
- AUST 0
- LEXX 1
- Target Price
- AUST N/A
- LEXX $4.00
- AVG Volume (30 Days)
- AUST 53.0K
- LEXX 200.9K
- Earning Date
- AUST 08-11-2025
- LEXX 07-14-2025
- Dividend Yield
- AUST N/A
- LEXX N/A
- EPS Growth
- AUST N/A
- LEXX N/A
- EPS
- AUST N/A
- LEXX N/A
- Revenue
- AUST N/A
- LEXX $615,923.00
- Revenue This Year
- AUST N/A
- LEXX $38.85
- Revenue Next Year
- AUST N/A
- LEXX $24.13
- P/E Ratio
- AUST N/A
- LEXX N/A
- Revenue Growth
- AUST N/A
- LEXX 49.85
- 52 Week Low
- AUST $0.80
- LEXX $0.79
- 52 Week High
- AUST $3.19
- LEXX $4.38
- Technical
- Relative Strength Index (RSI)
- AUST 45.25
- LEXX 40.69
- Support Level
- AUST $1.20
- LEXX $0.83
- Resistance Level
- AUST $1.40
- LEXX $1.05
- Average True Range (ATR)
- AUST 0.07
- LEXX 0.08
- MACD
- AUST -0.01
- LEXX -0.00
- Stochastic Oscillator
- AUST 36.36
- LEXX 21.65
About AUST Austin Gold Corp.
Austin Gold Corp is focused on the acquisition, exploration and evaluation of mineral resource properties in the western United States of America (USA). Exploration and development of mineral projects is considered the Company's single business segment. Its projects include Kelly Creek in Humboldt County, Lone Mountain and Miller in Elko County, and Stockade Mountain (Oregon).
About LEXX Lexaria Bioscience Corp.
Lexaria Bioscience Corp's patented drug delivery technology, DehydraTECH improves the way active pharmaceutical ingredients enter the bloodstream by promoting more effective oral delivery. DehydraTECH can increase bio-absorption with cannabinoids and nicotine by 5-10x and, in some instances with cannabinoids by as much as 27x compared to standard industry formulations, reduce the time of onset from 1-2 hours to minutes, and mask unwanted tastes. DehydraTECH has also evidenced an ability to deliver some drugs more effectively across the blood-brain barrier. The company has four reportable segments: Intellectual Property Licensing which generates maximum revenue, B2B Production, Research and Development, and Corporate. Geographically, it derives revenue from the United States and Canada.